Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000786

Drug Information
NameEtoposide
SynonymsSMR000112002; Prestwick2_000396; 4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin; Etoposide (VP16); Bio1_000489; SPBio_002532; MolPort-004-955-161; C01576; nchembio.573-comp8; CID284997; Demethyl Epipodophyllotoxin Ethylidine Glucoside; EINECS 251-509-1; Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside); CID6610299; Eposin, Vepesid, VP-16, Toposar, Etoposide; Demethyl-epiodophyllotoxin ethylidene glucoside; Vepeside; UNII-6PLQ3CP4P3; Ambap33419-42-0; Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside; NK 171; CPD000112002; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI); NChemBio.2007.10-comp19; 121471-01-0; HMS2052N05; 136598-18-0; Etoposido; VP-16-213; AC1L1FN8; CID3310; NSC141540; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside); AC1NR4OG; CHEBI:588795; D00125; 35317-32-9; VP 16-213; 4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside; NSC-141540; etoposide; CID36462; 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside); CID11758093; trans-Etoposide; VP-16; MolPort-004-905-001; Bio1_000978; Prestwick3_000396; nchembio873-comp2; AC1L1VT3; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside; Etoposidum; 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside; Demethylepipodophyllotoxin-beta-D-ethylideneglucoside; Eposin; AB00438905; ZINC03938684; MLS000049957; MLS002207239; Zuyeyidal; VP 16213; Etoposide (JP15/USP/INN); MLS001074951; Bio1_001467; NSC 141540; Etoposidum [INN-Latin]; Eposide; Etoposido [INN-Spanish]; CHEMBL44657; DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,; DB00773; AC1L6246; HSDB 6517; MLS002222184; CHEBI:4911; Prestwick_211; Epipodophyllotoxin-beta-D-ethyliden-glucoside, 4'-demethyl-; Toposar; I06-0248; LS-1214; VePesid; NCGC00025056-02; SAM001246880; AC1O4WGG; ZINC03830818; BRD-K37798499-001-02-5; AC1Q47JJ; AC1O7M1N; Lastet; CID5284558; Epipodophyllotoxin VP-16213; MLS002153463; VP 16 (pharmaceutical); VePESID (TN); KBioSS_002410; 33419-42-0; HMS1569O13; Etosid; S1225_Selleck; E0675; HMS2089F14; Prestwick0_000396; Etoposide [USAN:INN:BAN:JAN]; Prestwick1_000396; Etopophos (phosphate salt); CID6419930; MolPort-003-983-431; Etopol; 76576-58-4; BPBio1_000673; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside; CCRIS 2392; VP 16; 4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside; ST056353; 201594-04-9; 51854-34-3; MLS001424283; Vepesid J; E1383_SIGMA; ETOP; BSPBio_000611; (-)-Etoposide
Trade NameEposin; Etopophos; Vepesid; VP-16
IndicationCancers
[ICD9: 140-229   ICD10: C00-C96]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14
-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34
-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/
t11?,15?,20-,21?,22?,24-,25-,26?,27-,29+/m1/s1
InChIKeyVJJPUSNTGOMMGY-PTNNUCCUSA-N
Canonical SMILESCC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)
OC)O)OC)O)O    
Isomeric SMILESCC1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)OC3C4COC(=O)C4C(C5=CC6=C(C=
C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O
Therapeutic ClassAntineoplastic Agents
CAS NumberCAS 33419-42-0
FormulaC29H32O13
PubChem Compound IDCID 11758093.
PubChem Substance IDSID 16865881.
ChEBI4911;
SuperDrug ATC IDL01CB01
SuperDrug CAS ID033419420;
TargetDNA topoisomerase IIInhibitor[2][3][4]
Ref 1Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. To Reference
Ref 21,3-Dihydroxyacridone derivatives as inhibitors of herpes virus replication. Antiviral Res. 2000 Feb;45(2):123-34. To Reference
Ref 3Gametocytocidal activity of pyronaridine and DNA topoisomerase II inhibitors against multidrug-resistant Plasmodium falciparum in vitro. Parasitol Int. 2000 Feb;48(4):275-80. To Reference
Ref 4Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity. Anticancer Drug Des. 2000 Dec;15(6):413-21. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543